Results 181 to 190 of about 45,859 (253)

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?

Clinical Pharmacology &Therapeutics, EarlyView.
Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental ...
Gilbert J. Burckart, Susan M. Abdel‐Rahman, Gelareh Abulwerdi, Sherbet Samuels, Rebecca Racz, Mohamed A. Mohamoud, Nicholas P. Tatonetti   +6 more
wiley   +1 more source

Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation. [PDF]

Commun Med (Lond)
Akodad S, Niu X, Secades B, Stevens H.
europepmc   +1 more source

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

Clinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi, Mwila Mulubwa, Mmakwena M. Mmonwa, Mathew Njoroge, Liezl Krugmann, Kelly Chibale   +5 more
wiley   +1 more source

Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes. [PDF]

Front Cell Infect Microbiol
She P, Xiao D, Huang G, Guo S, Liu Y, Li M, Lu L, Hong Y, Wu Y.   +8 more
europepmc   +1 more source

Digital Transformation of Medicines Regulation in Africa—Perspectives from a Stakeholder Convening

Clinical Pharmacology &Therapeutics, EarlyView.
Regulatory authorities worldwide are developing strategies to integrate artificial intelligence (AI) into the lifecycle of health products, technologies, and medicines. While regulators share goals of improving efficiency, strengthening decision‐making, and protecting public health, their approaches differ according to institutional structures ...
Christelna Reyneke, Boitumelo Semete‐Makokotlela, Varnika Singh, Khanyisile Nkuku, Madelein Terblanche, Ezekiel T Mukanga, Nancy Ngum, Kudakwashe Dandajena, McNeil Chimus Mhango, Paulyne Wairimu, John Mwangi, Dominique Lagrave, Goonaseelan (Colin) Pillai   +12 more
wiley   +1 more source

Drug repurposing for Alzheimer's disease: a Delphi consensus and stakeholder consultation. [PDF]

Alzheimers Res Ther
Corbett A, Sultana J, Stych K, Mills R, Cummings JL, Williams G, Ismail Z, Soto-Martin M, Mintzer J, Gauthier S, Greig NH, Noble W, Killick R, Lai MKP, Routledge C, Walsh F, Fillit H, Aarsland D, Lane R, Mills K, Ballard C.   +20 more
europepmc   +1 more source

Repurposing Registries: Completeness of Real‐World Data for Regulatory and HTA Purposes in Three Cancer‐Focused Registries

Clinical Pharmacology &Therapeutics, EarlyView.
Despite developments in supporting the identification and selection of fit‐for‐purpose registries, a translational gap remains between the original purposes of clinically focused registries and their current and future expected use in policymaking. This study aimed to assess the extent to which cancer‐focused registries collect essential data elements ...
Manon C. Wilpshaar, Doranne Hilarius, Luisa Prada, Ansgar Weltermann, Christine Leopold   +4 more
wiley   +1 more source

Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions

Clinical Pharmacology &Therapeutics, EarlyView.
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects.
Maria J. Alfonso Arvez, Sam Wade, Darshna Goordeen, Jenni Ilomäki, Amanda J. Cross, Monica Langiu, George S. Q. Tan   +6 more
wiley   +1 more source

AI in drug repurposing for cancer therapies. [PDF]

Ann Med Surg (Lond)
Saddique MN, Abu Nahla U.
europepmc   +1 more source